Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3' Diindolylmethane (DIM)

被引:46
|
作者
Azmi, Asfar Sohail [1 ]
Ahmad, Aamir [1 ]
Banerjee, Sanjeev [1 ]
Rangnekar, Vivek M. [2 ]
Mohammad, Ramzi M. [3 ]
Sarkar, Fazlul H. [1 ]
机构
[1] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA
[2] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA
[3] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Internal Med, Detroit, MI 48201 USA
关键词
apoptosis; B-DIM; chemoprevention; pancreatic cancer; Par-4;
D O I
10.1007/s11095-008-9581-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Cancer chemoprevention is defined as the use of natural, synthetic, or biological agents to suppress, reverse or prevent the carcinogenic process from turning into aggressive cancer. Prostate apoptosis response-4 (Par-4) is a unique pro-apoptotic protein that selectively induces apoptosis in prostate cancer cells. However, its role in other malignancies has not been fully explored. This study tries to identify the functional significance of Par-4 in pancreatic cancer. Methods. Multiple molecular techniques such as Western blot analysis, trypan blue assay for cell viability, MTT assay for cell growth inhibition and Histone/DNA ELISA for apoptosis were used. Results. Western blot analysis revealed that 3,3'-diindolylmethane (DIM) a chemopreventive agent, specifically its more bioavailable formulation, B-DIM, at low doses (20 mu mol/L) induces Par-4, in L3.6pl and Colo-357 pancreatic cancer cells. At similar doses, DIM reduced cell viability and caused cell growth inhibition and apoptosis. Moreover, DIM pre-treatment sensitized the cells to cytotoxic action of chemotherapeutic drug gemcitabine through up-regulation of Par-4. Conclusion. The induction of Par-4 is indirectly related to increased sensitivity and cell death through apoptosis. To our knowledge the results reported here showed, for the first time, the induction of Par-4 by chemopreventive agents, in general, and DIM, in particular, in pancreatic cancer cells in vitro.
引用
收藏
页码:2117 / 2124
页数:8
相关论文
共 50 条
  • [21] PAR-4 as a possible new target for pancreatic cancer therapy
    Azmi, Asfar S.
    Philip, Philip A.
    Zafar, Syed F.
    Sarkar, Fazlul H.
    Mohammad, Ramzi M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (06) : 611 - 620
  • [22] A biomarker trial of BR-DIM (BioResponse 3,3′-Diindolylmethane) in patients with prostate cancer who undergo prostatectomy.
    Heath, E. I.
    Hwang, C.
    Cher, M. L.
    Heilbrun, L. K.
    Powell, I.
    Menon, M.
    Li, J.
    Heath, M.
    Sethi, S.
    Sarkar, F. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Benzo[a]pyrene toxicokinetics in humans following dietary supplementation with 3,3′-diindolylmethane (DIM) or Brussels sprouts
    Maier, Monica L. Vermillion
    Siddens, Lisbeth K.
    Pennington, Jamie M.
    Uesugi, Sandra L.
    Tilton, Susan C.
    Vertel, Emily A.
    Anderson, Kim A.
    Tidwell, Lane G.
    Ognibene, Ted J.
    Turteltaub, Kenneth W.
    Smith, Jordan N.
    Williams, David E.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2023, 460
  • [24] Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3,3′-Diindolylmethane (DIM)
    Lu, Lu
    Jiang, Mian
    Zhu, Changchun
    He, Junbo
    Fan, Saijun
    FREE RADICAL BIOLOGY AND MEDICINE, 2019, 130 : 244 - 255
  • [25] 3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
    Octavio Daniel Reyes-Hernández
    Gabriela Figueroa-González
    Laura Itzel Quintas-Granados
    Stephany Celeste Gutiérrez-Ruíz
    Hector Hernández-Parra
    Alejandra Romero-Montero
    María Luisa Del Prado-Audelo
    Sergio Alberto Bernal-Chavez
    Hernán Cortés
    Sheila I. Peña-Corona
    Lashyn Kiyekbayeva
    Dilek Arslan Ateşşahin
    Tamar Goloshvili
    Gerardo Leyva-Gómez
    Javad Sharifi-Rad
    Cancer Cell International, 23
  • [26] Comparative preclinical pharmacokinetics study of 3,3′-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?
    Mikhail Paltsev
    Vsevolod Kiselev
    Ekaterina Muyzhnek
    Vadim Drukh
    Igor Kuznetsov
    Olga Pchelintseva
    EPMA Journal, 2013, 4 (1):
  • [27] Comparative preclinical pharmacokinetics study of 3,3 '-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?
    Paltsev, Mikhail
    Kiselev, Vsevolod
    Muyzhnek, Ekaterina
    Drukh, Vadim
    Kuznetsov, Igor
    Pchelintseva, Olga
    EPMA JOURNAL, 2013, 4 (01):
  • [28] 3,3'-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
    Reyes-Hernandez, Octavio Daniel
    Figueroa-Gonzalez, Gabriela
    Quintas-Granados, Laura Itzel
    Gutierrez-Ruiz, Stephany Celeste
    Hernandez-Parra, Hector
    Romero-Montero, Alejandra
    Del Prado-Audelo, Maria Luisa
    Bernal-Chavez, Sergio Alberto
    Cortes, Hernan
    Pena-Corona, Sheila I.
    Kiyekbayeva, Lashyn
    Atessahin, Dilek Arslan
    Goloshvili, Tamar
    Leyva-Gomez, Gerardo
    Sharifi-Rad, Javad
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [29] The potential efficacy of 3,3′-diindolylmethane in prevention of prostate cancer development
    Fares, Fuad
    Azzam, Naiel
    Appel, Boaz
    Fares, Basem
    Stein, Avi
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2010, 19 (03) : 199 - 203
  • [30] Induction of apoptosis in MCF-7 and MDA-MB-231 human breast cancer cells by 3,3′-diindolylmethane (DIM)
    Hong, CB
    Firestone, GL
    Bjeldanes, LF
    FASEB JOURNAL, 2001, 15 (04): : A600 - A600